Michael A. Vogelbaum

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 397 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 327 citations · Full text

Medicine, Oncology, Pharmacology +16

Results of a phase II trial of the GliaSite Radiation Therapy System for the treatment of newly diagnosed, resected single brain metastases

Lisa R. Rogers, Jack Rock, Allen K. Sills et al. · Journal of neurosurgery · 2006 · 102 citations

Medicine, Oncology, Radiation Oncology +16

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

C. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al. · Neuro-Oncology · 2021 · 63 citations · Full text

Medicine, Oncology, Pathology +17

Use of the Radiation Therapy Oncology Group recursive partitioning analysis classification system and predictors of survival in 19 women with brain metastases from ovarian carcinoma

Philip G. Chen, Shih‐Yuan Lee, Gene H. Barnett et al. · Cancer · 2005 · 35 citations · Full text

Medicine, Oncology, Surgery +14